Literature DB >> 17978026

The roles of kinases in familial Parkinson's disease.

Mark R Cookson1, William Dauer, Ted Dawson, Edward A Fon, Ming Guo, Jie Shen.   

Abstract

The purpose of this mini-symposium is to discuss some of the inherited forms of Parkinson's disease (PD) in view of recent data suggesting that some of the proteins affect cellular signaling pathways. As an illustration, we shall focus on two different kinases associated with recessive and dominant forms of PD. Mutations in the mitochondrial kinase PTEN (phosphatase and tensin homolog)-induced kinase 1 (PINK1) are loss-of-function mutations in a normally neuroprotective protein. Loss-of-function mutations in model organisms have variable effects, from dramatic muscle and spermatid defects in Drosophila to more subtle neurophysiological abnormalities in mice. Several lines of evidence relate these to the action of a second gene for familial PD, parkin, an E3 ubiquitin ligase shown recently to have effects on Akt signaling. Mutations in leucine-rich repeat kinase 2 (LRRK2), a cytosolic kinase, are dominant and have the opposite effect of causing neuronal damage. The mechanism(s) involved are uncertain at this time because LRRK2 is a large and complex molecule with several domains. Increased kinase activity accounts for the action of at least some of the mutations, suggesting that hyperactive or misregulated kinase activity may lead to the damaging effects of LRRK2 in neurons. For both PINK1 and LRRK2, the following key question that needs to be answered: what are the physiological substrates that mediate effects in cells? Here, we will discuss some of the recent thinking about physiological and pathological roles for signaling in PD and how these may have therapeutic implications for the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978026      PMCID: PMC6673380          DOI: 10.1523/JNEUROSCI.3695-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  35 in total

1.  Association between early-onset Parkinson's disease and mutations in the parkin gene.

Authors:  C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

Review 2.  Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins.

Authors:  Linda Hicke; Rebecca Dunn
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

3.  Molecular determinants for the complex binding specificity of the PDZ domain in PICK1.

Authors:  Kenneth L Madsen; Thijs Beuming; Masha Y Niv; Chiun-Wen Chang; Kumlesh K Dev; Harel Weinstein; Ulrik Gether
Journal:  J Biol Chem       Date:  2005-03-17       Impact factor: 5.157

4.  Parkin-deficient mice are not a robust model of parkinsonism.

Authors:  Francisco A Perez; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

5.  Loss of locus coeruleus neurons and reduced startle in parkin null mice.

Authors:  Rainer Von Coelln; Bobby Thomas; Joseph M Savitt; Kah Leong Lim; Masayuki Sasaki; Ellen J Hess; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Authors:  Matthew S Goldberg; Sheila M Fleming; James J Palacino; Carlos Cepeda; Hoa A Lam; Anushree Bhatnagar; Edward G Meloni; Nanping Wu; Larry C Ackerson; Gloria J Klapstein; Mahadevan Gajendiran; Bryan L Roth; Marie-Francoise Chesselet; Nigel T Maidment; Michael S Levine; Jie Shen
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

7.  Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.

Authors:  Jean-Michel Itier; Pablo Ibanez; Maria Angeles Mena; Nacer Abbas; Charles Cohen-Salmon; Georg Andrees Bohme; Michel Laville; Jeremy Pratt; Olga Corti; Laurent Pradier; Gwenaelle Ret; Chantal Joubert; Magali Periquet; Francisco Araujo; Julia Negroni; Maria Jose Casarejos; Santiago Canals; Rosa Solano; Alba Serrano; Eva Gallego; Marina Sanchez; Patrice Denefle; Jesus Benavides; Gunter Tremp; Thomas A Rooney; Alexis Brice; Justo Garcia de Yebenes
Journal:  Hum Mol Genet       Date:  2003-07-22       Impact factor: 6.150

8.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

9.  Hereditary early-onset Parkinson's disease caused by mutations in PINK1.

Authors:  Enza Maria Valente; Patrick M Abou-Sleiman; Viviana Caputo; Miratul M K Muqit; Kirsten Harvey; Suzana Gispert; Zeeshan Ali; Domenico Del Turco; Anna Rita Bentivoglio; Daniel G Healy; Alberto Albanese; Robert Nussbaum; Rafael González-Maldonado; Thomas Deller; Sergio Salvi; Pietro Cortelli; William P Gilks; David S Latchman; Robert J Harvey; Bruno Dallapiccola; Georg Auburger; Nicholas W Wood
Journal:  Science       Date:  2004-04-15       Impact factor: 47.728

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  22 in total

1.  Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.

Authors:  Byoung Dae Lee; Xiaojie Li; Ted M Dawson; Valina L Dawson
Journal:  Methods Mol Biol       Date:  2012

Review 2.  E3 ubiquitin ligases in protein quality control mechanism.

Authors:  Deepak Chhangani; Ajay Prakash Joshi; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

3.  LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Authors:  Chen Yao; Rabih El Khoury; Wen Wang; Tara A Byrd; Elizabeth A Pehek; Colin Thacker; Xiongwei Zhu; Mark A Smith; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Neurobiol Dis       Date:  2010-04-09       Impact factor: 5.996

4.  Beyond the mitochondrion: cytosolic PINK1 remodels dendrites through protein kinase A.

Authors:  Ruben K Dagda; Irene Pien; Ruth Wang; Jianhui Zhu; Kent Z Q Wang; Jason Callio; Tania Das Banerjee; Raul Y Dagda; Charleen T Chu
Journal:  J Neurochem       Date:  2013-11-13       Impact factor: 5.372

Review 5.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

6.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.

Authors:  G Martella; P Platania; D Vita; G Sciamanna; D Cuomo; A Tassone; A Tscherter; T Kitada; P Bonsi; J Shen; A Pisani
Journal:  Exp Neurol       Date:  2008-11-21       Impact factor: 5.330

Review 7.  Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.

Authors:  Ruben K Dagda; Charleen T Chu
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

8.  GTPase activity plays a key role in the pathobiology of LRRK2.

Authors:  Yulan Xiong; Candice E Coombes; Austin Kilaru; Xiaojie Li; Aaron D Gitler; William J Bowers; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  PLoS Genet       Date:  2010-04-08       Impact factor: 5.917

9.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

10.  Phosphorylation of ATXN1 at Ser776 in the cerebellum.

Authors:  Nathan D Jorgensen; J Michael Andresen; Sara Lagalwar; Ben Armstrong; Sam Stevens; Courtney E Byam; Lisa A Duvick; Shaojuan Lai; Paymaan Jafar-Nejad; Huda Y Zoghbi; H Brent Clark; Harry T Orr
Journal:  J Neurochem       Date:  2009-05-15       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.